SLE 临床试验结局指标的一致性与不一致性:三项阿尼鲁单抗 2/3 期试验分析
该分析基于 TULIP-1、TULIP-2 和 MUSE 三项随机 52 周试验,评估阿尼鲁单抗治疗系统性红斑狼疮患者第 52 周 BICLA 与 SRI(4) 结局的一致性。多数患者(78%-85%)两种结局一致,双应答率均偏向阿尼鲁单抗;TULIP-1 中识别出 BICLA 无应答/SRI(4) 应答亚组(40/364,11%),安慰剂组多于阿尼鲁单抗组。
要点
- 多数患者(78%-85%)BICLA 与 SRI(4) 结局一致。
- 三项试验双 BICLA/SRI(4) 应答率均偏向阿尼鲁单抗(名义 p≤0.004)。
- TULIP-1 中 BICLA 无应答/SRI(4) 应答亚组(40/364,11%)以安慰剂组患者居多(n=28 vs n=12)。
核心结论
- 跨试验多数患者 BICLA 与 SRI(4) 结局一致,双 BICLA/SRI(4) 应答偏向阿尼鲁单抗。
- TULIP-1 中识别出 BICLA 无应答/SRI(4) 应答亚组,驱动 BICLA/SRI(4) 不一致的关键因素(疾病活动度、糖皮质激素减量)失衡不成比例地偏向安慰剂组。
- 未来 SLE 试验需仔细关注基线疾病活动度并监测糖皮质激素减量差异。
研究设计与样本
- TULIP-1、TULIP-2(均为 3 期)和 MUSE(2b 期)为随机 52 周试验,评估静脉阿尼鲁单抗(每 4 周 300 mg,共 48 周)或安慰剂。
- 阿尼鲁单抗组样本量:TULIP-1/TULIP-2 n=180;MUSE n=99;安慰剂组:TULIP-1 n=184,TULIP-2 n=182;MUSE n=102。
- 对每例患者评估第 52 周 BICLA 和 SRI(4) 结局。
主要发现
- 多数患者(78%-85%)BICLA 与 SRI(4) 结局一致(Cohen's Kappa 0.6-0.7,名义 p<0.001)。
- 双 BICLA/SRI(4) 应答率在 TULIP-1、TULIP-2 和 MUSE 中均偏向阿尼鲁单抗而非安慰剂(所有名义 p≤0.004)。
- TULIP-1 中识别出 BICLA 无应答/SRI(4) 应答亚组(40/364,占 TULIP-1 人群 11%),其中安慰剂组患者(n=28)多于阿尼鲁单抗组(n=12)。
- 该亚组中,安慰剂治疗患者基线疾病活动度、关节计数和糖皮质激素减量率较低,且安慰剂治疗患者中关节炎应答者多于阿尼鲁单抗治疗患者。
关键数值与推荐
- BICLA 与 SRI(4) 一致率:78%-85%(Cohen's Kappa 0.6-0.7,名义 p<0.001)。
- 双 BICLA/SRI(4) 应答率偏向阿尼鲁单抗:TULIP-1、TULIP-2 和 MUSE 所有名义 p≤0.004。
- BICLA 无应答/SRI(4) 应答亚组:40/364,占 TULIP-1 人群 11%,安慰剂组 n=28 vs 阿尼鲁单抗组 n=12。
临床怎么用
- 作者认为,未来 SLE 试验中仔细关注基线疾病活动度和监测糖皮质激素减量差异将至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In the anifrolumab systemic lupus erythematosus (SLE) trial programme, there was one trial (TULIP-1) in which BILAG-based Composite Lupus Assessment (BICLA) responses favoured anifrolumab over placebo, but the SLE Responder Index (SRI(4)) treatment difference was not significant. We investigated the degree of concordance between BICLA and SRI(4) across anifrolumab trials in order to better understand drivers of discrepant SLE trial results. METHODS: TULIP-1, TULIP-2 (both phase 3) and MUSE (phase 2b) were randomised, 52-week trials of intravenous anifrolumab (300 mg every 4 weeks, 48 weeks; TULIP-1/TULIP-2: n=180; MUSE: n=99) or placebo (TULIP-1: n=184, TULIP-2: n=182; MUSE: n=102). Week 52 BICLA and SRI(4) outcomes were assessed for each patient. RESULTS: Most patients (78%-85%) had concordant BICLA and SRI(4) outcomes (Cohen's Kappa 0.6-0.7, nominal p<0.001). Dual BICLA/SRI(4) response rates favoured anifrolumab over placebo in TULIP-1, TULIP-2 and MUSE (all nominal p≤0.004). A discordant TULIP-1 BICLA non-responder/SRI(4) responder subgroup was identified (40/364, 11% of TULIP-1 population), comprising more patients receiving placebo (n=28) than anifrolumab (n=12). In this subgroup, placebo-treated patients had lower baseline disease activity, joint counts and glucocorticoid tapering rates, and more placebo-treated patients had arthritis response than anifrolumab-treated patients. CONCLUSIONS: Across trials, most patients had concordant BICLA/SRI(4) outcomes and dual BICLA/SRI(4) responses favoured anifrolumab. A BICLA non-responder/SRI(4) responder subgroup was identified where imbalances of key factors driving the BICLA/SRI(4) discordance (disease activity, glucocorticoid taper) disproportionately favoured the TULIP-1 placebo group. Careful attention to baseline disease activity and monitoring glucocorticoid taper variation will be essential in future SLE trials. TRIAL REGISTRATION NUMBERS: NCT02446912 and NCT02446899.
引用
- Bruce IN, Furie RA, Morand EF, et al. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022. PMID: 35580976. doi:10.1136/annrheumdis-2021-221847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。